Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Solidion Technology′s 30+ Patents for Space-Based Artificial Intelligence Batteries Include the... (PR Newswire) +++ SOLIDION Aktie +11,17%

ELANCO Aktie

 >ELANCO Aktienkurs 
21.41 EUR    +0.7%    (TradegateBSX)
Ask: 21.67 EUR / 280 Stück
Bid: 21.16 EUR / 290 Stück
Tagesumsatz: 112 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
ELANCO Aktie über LYNX handeln
>ELANCO Performance
1 Woche: +6,4%
1 Monat: +12,9%
3 Monate: +4,8%
6 Monate: +16,7%
1 Jahr: +86,3%
laufendes Jahr: +13,8%
>ELANCO Aktie
Name:  ELANCO ANIMAL HEALTH.
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US28414H1032 / A2N6BH
Symbol/ Ticker:  5EA (Frankfurt) / ELAN (NYSE)
Kürzel:  FRA:5EA, ETR:5EA, 5EA:GR, NYSE:ELAN
Index:  -
Webseite:  https://www.elanco.com/
Profil:  Elanco Animal Health Incorporated is a leading global pharmaceutical company specializing in animal health. Its primary function is the development and delivery of innovative products and solutions to prevent and treat diseases in both companion anim..
>Volltext..
Marktkapitalisierung:  10543.41 Mio. EUR
Unternehmenswert:  13620.01 Mio. EUR
Umsatz:  4203.97 Mio. EUR
EBITDA:  851.45 Mio. EUR
Nettogewinn:  -207.92 Mio. EUR
Gewinn je Aktie:  -0.42 EUR
Schulden:  3428.99 Mio. EUR
Liquide Mittel:  367.73 Mio. EUR
Operativer Cashflow:  -
Bargeldquote:  0.26
Umsatzwachstum:  3.49%
Gewinnwachstum:  -160.75%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  2 Insider kauften innerhalb der letzten 30 Tage Aktien im Wert von 172.006 Euro.
Suchwörter:  ELANCO
Letzte Datenerhebung:  05.06.26
>ELANCO Kennzahlen
Aktien/ Unternehmen:
Aktien: 499.45 Mio. St.
Frei handelbar: 98.97%
Rückkaufquote: -
Mitarbeiter: 9900
Umsatz/Mitarb.: 0.41 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 33.25%
Bewertung:
KGV: -
KGV lG: 21.21
KUV: 2.06
KBV: 1.71
PEG-Ratio: -
EV/EBITDA: 16
Rentabilität:
Bruttomarge: 43.76%
Gewinnmarge: -4.95%
Operative Marge: 6.13%
Managementeffizenz:
Gesamtkaprendite: -1.85%
Eigenkaprendite: -3.77%
>ELANCO Peer Group
Gesundheit, Tiermedizin/ Tierbehandlung
 
04.06.26 - 18:30
Elanco Animal Health Commits to Supporting U.S. Livestock Producers and Pet Owners in Fight Against New World Screwworm (Accesswire)
 
Company offers portfolio of treatment options and expert guidance following first confirmed case in the United StatesNew World screwworm has officially reached the United States, with the first con......
03.06.26 - 13:30
New Research Reveals Pet Spending as a "Protected Budget Item" for Owners, Fueling Industry Resilience (PR Newswire)
 
INDIANAPOLIS, June 3, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN), a global leader in animal health, today released new consumer research showing pet owners continue to prioritize spending on their pets, underscoring the robust and resilient nature of the industry.......
27.05.26 - 18:18
Elanco: Monumental Public-Private Initiative Forms to Permanently Close America′s Protein Gap (Accesswire)
 
America's Farmers, Protein Industry, Hunger Advocates Launch $40 Million Initiative to Deliver 3 Billion Protein-Rich Meals Annually NORTHAMPTON, MA / ACCESS Newswire / May 27, 2026 / On the eve of......
20.05.26 - 00:01
Insiderhandel: PRESIDENT, CEO AND DIRECTOR kauft Aktien von Elanco Animal Health im Wert von 99843 USD (Insiderkauf)
 
Simmons, Jeffrey N. - Vorstand - Tag der Transaktion: 2026-05-15...
20.05.26 - 00:01
Insiderhandel: Vorstand kauft Aktien von Elanco Animal Health im Wert von 99939 USD (Insiderkauf)
 
Modi, Rajeev A. - Vorstand - Tag der Transaktion: 2026-05-15...
18.05.26 - 13:30
Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market (PR Newswire)
 
Phased launch of new anti-IL-31 monoclonal antibody is now underway, with product being used by select Early Experience Program veterinarians in clinics today Befrena is effective for the treatment of dogs against allergic dermatitis and canine atopic dermatitis with no age or weight......
12.05.26 - 21:12
Earnings Call Transkript: Elanco übertrifft Prognosen für Q1 2026 mit starkem Wachstum (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
07.05.26 - 23:18
Elanco Animal Health Boosts Full Year Forecast (Bloomberg)
 
Elanco Animal Health boosted its adjusted earnings per share forecast for the full year. Jeff Simmons, President and CEO at Elanco Animal Health joins Bloomberg Businessweek Daily to discuss their company earnings and how the pet care market is doing. (Source: Bloomberg)...
06.05.26 - 23:48
Elanco outlines 5%-7% organic growth and $1.03-$1.09 adjusted EPS as innovation target rises to $1.2B (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
06.05.26 - 18:36
Elanco (ELAN) Q1 2026 Earnings Transcript (Fool)
 
Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...
06.05.26 - 15:48
Starkes Wachstum: Elanco übertrifft im Q1 2026 die Erwartungen und erhöht die Jahresprognose (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
06.05.26 - 15:15
Elanco Animal Health Incorporated (ELAN) Beats Q1 Earnings and Revenue Estimates (Zacks)
 
Elanco Animal Health (ELAN) delivered earnings and revenue surprises of +16.28% and +6.93%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?...
06.05.26 - 12:33
Elanco Non-GAAP EPS of $0.40 beats by $0.06, revenue of $1.37B beats by $90M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
06.05.26 - 12:30
Elanco Animal Health Reports First Quarter 2026 Results (PR Newswire)
 
Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target First Quarter 2026 Financial Results: Revenue of $1,371 million, an increase of 15% year-over-year; 10% organic constant currency growth Reported Net Income of $57 million, Adjusted Net Income of......
05.05.26 - 18:03
Elanco Q1 2026 Earnings Preview (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
29.04.26 - 17:30
Analysts Estimate Elanco Animal Health Incorporated (ELAN) to Report a Decline in Earnings: What to Look Out for (Zacks)
 
Elanco Animal Health (ELAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....
28.04.26 - 00:27
Elanco′s Negasunt™ Powder (Coumaphos, Propoxur, Sulfanilamide Topical Powder) and Tanidil™ (Coumaphos, Propoxur) Receive Emergency Authorization for Use Against New World Screwworm in Livestock (PR Newswire)
 
Action Prepares Veterinarians and Livestock Producers with Prevention and Treatment Options Prior to Fly Being Detected in the U.S. Federal agencies grant emergency authorizations for New World screwworm in livestock, reinforcing Elanco's leadership in livestock health innovations Actions......
24.04.26 - 15:03
National Veterinary Associates Appoints Todd S. Young as Chief Financial Officer (Business Wire)
 
AUSTIN, Texas--(BUSINESS WIRE)--National Veterinary Associates (NVA) announced the appointment of Todd S. Young as Chief Financial Officer, effective May 1, 2026. Young will serve on the company's executive leadership team and report to Chief Executive Officer John Bruno. “I am thrilled to welcome Todd to NVA," said Bruno. "He has spent his career leading world-class finance teams in human and animal healthcare, and his public company experience and deep industry knowledge are exactly what we need as we enter our next phase of growth." Young brings more than 25 years across human and animal healthcare, including more than a decade as a public company CFO. Most recently, he served as CFO of Acadia Healthcare (NASDAQ: ACHC), a leader in the behavioral healthcare industry, where he drove financial discipline and operational performance across its network. Before Acadia, Young served as EVP and CFO at Elanco (NYSE: ELAN), one of the world's largest independent animal health companies, where...
16.04.26 - 14:06
Elanco Confirms Date and Conference Call for First Quarter 2026 Financial Results Announcement (PR Newswire)
 
INDIANAPOLIS, April 16, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its first quarter 2026 financial results on Wednesday, May 6, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Dem Morgenrot und dem Frauenrat ist nicht zu trauen. - Sprichwort Frankreich
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!